Company: ZVRA
Filing Date: 2025-04-24
Form Type: PRRN14A
Source: 0000897069-25-000871
Chunk: 2

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-24
Form: PRRN14A
Chunk 2
---
s for Our Solicitation” for further information on the importance of electing the Nominees. I believe declassification would provide stockholders the ability to evaluate each director annually, which is viewed by many institutional stockholders as increasing the accountability of directors to such stockholders. With regard to using a majority vote standard for the election of directors in uncontested elections, I believe this would give stockholders a greater voice because it eliminates the ability of a small minority of stockholders, or even as few as one stockholder, to elect directors. As noted above, the other issue of concern to me is the Company’s executive compensation, which I believe is excessive. In fact, stockholders seem to support this belief as they voted against the Company’s request to expand the available stock option pool after the Board had exhausted the existing pool. Unfortunately, to continue to provide themselves additional equity, management and the Board were able to circumvent the stockholder vote against the proposal by, among other things, greatly increasing the number of shares outstanding through a highly dilutive stock offering. 2 I believe these poor governance practices have resulted in the stock languishing despite the approval and successful initial launch of MIPLYFFA™ and subsequent sale of the PRV. My goal as a long-term stockholder of Zevra is for an independent Board to act in the best interests of all stockholders and follow best practices in corporate governance and executive compensation. While my Nominees favor good corporate governance practices, they have not agreed to vote or act on the above corporate governance practices in any particular manner, as they take their fiduciary duties seriously and will only take action after being fully informed and determining what is in the best interests of the Company and its stockholders. I have no desire to actively manage the Company. I am supportive of the strategic direction of the Company and have invested significant capital to support the Company for many years; long before the approval of MIPLYFFA™ was a near certainty. My goal is simple, to establish a Board of Directors who are committed to best practices in governance and executive compensation focused on maximizing value for all stockholders. If elected, the Nominees, together with the Proponent’s three nominees who were elected at the 2023 annual meeting, will constitute a majority on the Board and will potentially be able to implement any actions that they may believe are necessary to unlock stockholder value. That said none of the current Nominees nor any of the prior three nominees is a party to any agreement, arrangement or understanding